---
company: LABCORP HOLDINGS INC.
ticker: LH
form: 8-K
filed: 2026-07-30
accession: 0000920148-26-000162
source: https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/
---

# Labcorp Holdings (LH) earnings release, July 30, 2026

Labcorp Holdings Inc. (LH) · Form 8-K, Item 2.02 · Filed 2026-07-30 · [SEC filing](https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/)

Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance

• Results from operations for second quarter 2026 versus second quarter 2025:

◦ Revenue: $3.73 billion vs. $3.53 billion, up 5.8%

◦ Diluted EPS: $3.64 vs. $2.84, up 28.5%

◦ Adjusted EPS: $4.99 vs. $4.35, up 14.9%

• Raised full-year enterprise revenue growth and adjusted EPS guidance:

◦ Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint

◦ Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint

• Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion

• Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence

• Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights

BURLINGTON, N.C., July 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance.

“Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business,” said Adam Schechter, Chairman and CEO of Labcorp. “During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders.”¹

Labcorp continues to advance its strategic priorities:

Lead in specialty testing, with several advancements in Labcorp Oncology:

• Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity.

• Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense’s primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio.

• Entered into a clinical trial collaboration with Fox Chase Cancer Center to evaluate Labcorp’s Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence.

• Expanded nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca’s targeted therapy TRUQAP.

Be a partner of choice for health systems and regional/local laboratories:

• Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide.

• Completed the acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio.

• Completed the acquisition of Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas.

Grow Consumer Health

:

• Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source.

• Introduced Canada's first at-home, self-collection test to measure women’s fertility-related hormones and men’s testosterone levels.

• Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health.

Shape our future through technology and innovation:

• Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic’s Aura platform.

• Enhanced the patient experience at Labcorp’s Patient Service Centers, through expanded appointment availability, streamlined scheduling, and proactive rescheduling reminders and assistance.²

Labcorp also remains committed to a disciplined allocation of capital. In the second quarter of 2026, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. The company also paid down $500.0 million in senior notes in June. On July 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on September 11, 2026, to stockholders of record at the close of business on August 28, 2026. In July, the Board of Directors approved an increase of $1.0 billion in the company's share repurchase authorization, bringing the remaining total authorization to $1.4 billion.³

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS⁴

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Capital Allocation Summary

• At the end of the quarter, Labcorp's cash and cash equivalents balance was $141.8 million and total debt was $5.86 billion. In June, we retired $500.0 million in senior notes.

• During the quarter, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends.⁵

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Diagnostics Laboratories Segment Summary⁶

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Biopharma Laboratory Services Segment Summary⁷

Guidance for 2026... (truncated)t from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.⁸

Use of Adjusted Measures

The company has provided in this press release and accompanying tables “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company’s financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise “special items” used for certain adjusted financial information are included in the tables accompanying this press release.

The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.

A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the “Events” section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.⁹

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

C autionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company’s former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company’s information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.... (truncated)mation in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading “MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS”.

- End of Text -

- Tables to Follow -¹⁰

## Financial statements

### Income Statement (Three Months Ended June 30, — CONSOLIDATED RESULTS)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – Delta | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – Delta |
|---|---:|---:|---:|---:|---:|---:|---:|
| Total Revenue | 3,731.1 |  | 3,527.3 | 5.8 | 7,268.7 | 6,872.4 | 5.8 |
| Organic(1) |  |  |  | 4.2 |  |  | 3.6 |
| Acquisitions, net of Divestitures(2) |  |  |  | 1.2 |  |  | 1.3 |
| Foreign Exchange |  |  |  | 0.4 |  |  | 0.9 |
| (1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development. | (1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development. |  | (1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development. |  | (1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development. | (1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development. |  |
| (2) Includes the impact from strategic actions taken in Early Development. | (2) Includes the impact from strategic actions taken in Early Development. |  | (2) Includes the impact from strategic actions taken in Early Development. |  | (2) Includes the impact from strategic actions taken in Early Development. | (2) Includes the impact from strategic actions taken in Early Development. |  |
| Earnings Summary (Dollars in millions, except per share data) | Earnings Summary (Dollars in millions, except per share data) |  | Earnings Summary (Dollars in millions, except per share data) |  |  |  |  |
| Operating Income (“OI”) | 451.6 |  | 394.5 |  | 832.4 | 720.5 |  |
| OI as % of Revenue | 12.1% |  | 11.2% | 90 bps | 11.5% | 10.5% | 100 bps |
| Adjustments (3) | 137.1 |  | 137.1 |  | 264.2 | 280.1 |  |
| Adjusted Operating Income (“AOI”) (4) | 588.7 | -5 | 531.6 |  | 1,096.6 | 1,000.6 |  |
| AOI as % of Revenue | 15.8% | -5 | 15.1% | 70 bps | 15.1% | 14.6% | 50 bps |
| Net Earnings Attributable to Labcorp Holdings Inc. | 298.7 |  | 237.9 |  | 576.5 | 450.7 |  |
| Diluted EPS | 3.64 |  | 2.84 |  | 6.99 | 5.36 |  |
| Adjusted EPS (4) | 4.99 |  | 4.35 | 14.9 | 9.24 | 8.19 | 12.8 |
| (3) Adjustments include amortization, impairment charges, restructuring charges, and special items. | (3) Adjustments include amortization, impairment charges, restructuring charges, and special items. |  | (3) Adjustments include amortization, impairment charges, restructuring charges, and special items. |  | (3) Adjustments include amortization, impairment charges, restructuring charges, and special items. | (3) Adjustments include amortization, impairment charges, restructuring charges, and special items. |  |
| (4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. | (4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. |  | (4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. |  | (4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. | (4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. |  |
| (5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies. | (5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies. |  | (5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies. |  | (5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies. | (5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies. |  |

### Income Statement (Three Months Ended June 30, — Diagnostics Laboratories Segment Summary (in millions))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – Delta |
|---|---:|---:|---:|---:|
| Total Revenue | 2,900.7 |  | 2,748.8 | 5.5 |
| Organic |  |  |  | 3.6 |
| Acquisitions, net of Divestitures |  |  |  | 1.9 |
| Earnings Summary (1) (Dollars in millions) | Earnings Summary (1) (Dollars in millions) |  |  |  |
| Adjusted Operating Income (“AOI”) (2) | 522.6 | -3 | 482.8 |  |
| AOI as % of Revenue | 18.0% | -3 | 17.6% | 50 bps |
| (1) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. | (1) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. |  | (1) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information. |  |
| (2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses. | (2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses. |  | (2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses. |  |
| (3) Adjusted Operating Income and margin increased due to organic growth and operating efficiencies. | (3) Adjusted Operating Income and margin increased due to organic growth and operating efficiencies. |  | (3) Adjusted Operating Income and margin increased due to organic growth and operating efficiencies. |  |

### Income Statement (Three Months Ended June 30, — Biopharma Laboratory Services Segment Summary (in millions))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – Delta |
|---|---:|---:|---:|---:|
| Total Revenue | 836.2 |  | 784.8 | 6.5 |
| Organic(2) |  |  |  | 6.2 |
| Acquisitions, net of Divestitures(3) |  |  |  | -1.4 |
| Foreign Exchange |  |  |  | 1.8 |

### Income Statement (Three Months Ended June 30, — (In Millions, Except Per Share Data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues | 3,731.1 | 3,527.3 | 7,268.7 | 6,872.4 |
| Cost of revenues | 2,619.1 | 2,481.1 | 5,142.9 | 4,878.2 |
| Gross profit | 1,112 | 1,046.2 | 2,125.8 | 1,994.2 |
| Selling, general, and administrative expenses | 577.2 | 579.3 | 1,128.2 | 1,125.3 |
| Amortization of intangibles and other assets | 78.1 | 68.3 | 153.7 | 137.9 |
| Restructuring and other charges | 5.1 | 4.1 | 11.5 | 10.5 |
| Operating income | 451.6 | 394.5 | 832.4 | 720.5 |
| Other (expense) income: | Interest expense | -61.1 | -57.1 | -116.2 | -113.1 |
| Other (expense) income: | Investment income | 5.6 | 1.7 | 17.8 | 8.2 |
| Other (expense) income: | Equity method loss, net | -6.2 | -1.7 | -11.3 | -2 |
| Other (expense) income: | Other, net | -3.5 | -32.7 | -16.6 | -33.7 |
| Other (expense) income: | Earnings from operations before income taxes | 386.4 | 304.7 | 706.1 | 579.9 |
| Other (expense) income: | Provision for income taxes | 87.3 | 66.4 | 129 | 128.6 |
| Other (expense) income: | Net earnings | 299.1 | 238.3 | 577.1 | 451.3 |
| Other (expense) income: | Less: Net earnings attributable to the noncontrolling interest | -0.4 | -0.4 | -0.6 | -0.6 |
| Other (expense) income: | Net earnings attributable to Labcorp Holdings Inc. | 298.7 | 237.9 | 576.5 | 450.7 |
| Earnings per common share: | Basic earnings per common share | 3.66 | 2.85 | 7.03 | 5.4 |
| Earnings per common share: | Diluted earnings per common share | 3.64 | 2.84 | 6.99 | 5.36 |
| Earnings per common share: | Weighted-average basic common shares outstanding | 81.7 | 83.4 | 82 | 83.5 |
| Earnings per common share: | Weighted-average diluted common shares outstanding | 82 | 83.9 | 82.4 | 84.1 |

### Income Statement (Three Months Ended June 30, — (Dollars in Millions) (in millions))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Diagnostics Laboratories | Revenues | 2,900.7 | 2,748.8 | 5,662.8 | 5,378.4 |
| Diagnostics Laboratories | Adjusted operating income | 522.6 | 482.8 | 981.3 | 910.3 |
| Diagnostics Laboratories | Adjusted operating margin | 18.0% | 17.6% | 17.3% | 16.9% |
| Biopharma Laboratory Services | Revenues | 836.2 | 784.8 | 1,616.8 | 1,506.1 |
| Biopharma Laboratory Services | Adjusted operating income | 142.2 | 123.3 | 262.9 | 230.2 |
| Biopharma Laboratory Services | Adjusted operating margin | 17.0% | 15.7% | 16.3% | 15.3% |
| Consolidated | Revenues | 3,731.1 | 3,527.3 | 7,268.7 | 6,872.4 |
| Consolidated | Adjusted segment operating income | 664.8 | 606.1 | 1,244.2 | 1,140.5 |
| Consolidated | Unallocated corporate expense | -76.1 | -74.5 | -147.6 | -139.9 |
| Consolidated | Consolidated adjusted operating income | 588.7 | 531.6 | 1,096.6 | 1,000.6 |
| Consolidated | Adjusted operating margin | 15.8% | 15.1% | 15.1% | 14.6% |

### Income Statement (Three Months Ended June 30, — (Dollars and Shares in Millions, Except Per Share Data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Adjusted Operating Income | Operating income | 451.6 | 394.5 | 832.4 | 720.5 |
| Adjusted Operating Income | Amortization of intangibles and other assets (a) | 78.1 | 68.3 | 153.7 | 137.9 |
| Adjusted Operating Income | Restructuring and other charges (b) | 5.1 | 4.1 | 11.5 | 10.5 |
| Adjusted Operating Income | Acquisition and disposition-related costs (c) | 21.3 | 15.1 | 31.2 | 44.2 |
| Adjusted Operating Income | LaunchPad costs (d) | 11.7 | 17.2 | 24.7 | 37.3 |
| Adjusted Operating Income | Other | 20.9 | 31.9 | 43.1 | 46.4 |
| Adjusted Operating Income | TSA reimbursement (e) |  | 0.5 |  | 3.8 |

### Balance Sheet (June 30, 2026 — (In Millions) (in millions))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 141.8 | 532.3 |
| Current assets: | Accounts receivable, net | 2,342.4 | 2,103.8 |
| Current assets: | Unbilled services, net | 162.4 | 156.9 |
| Current assets: | Supplies inventory | 562.2 | 534.7 |
| Current assets: | Prepaid expenses and other | 606.1 | 692.8 |
| Current assets: | Total current assets | 3,814.9 | 4,020.5 |
| Current assets: | Property, plant, and equipment, net | 3,100.5 | 3,081.5 |
| Current assets: | Goodwill, net | 7,030.1 | 6,789.5 |
| Current assets: | Intangible assets, net | 3,678.2 | 3,596 |
| Current assets: | Joint venture partnerships and equity method investments | 139.3 | 153.9 |
| Current assets: | Other assets, net | 769.3 | 751.3 |
| Current assets: | Total assets | 18,532.3 | 18,392.7 |
| Current liabilities: | Accounts payable | 688.5 | 840.8 |
| Current liabilities: | Accrued expenses and other | 862.4 | 847.8 |
| Current liabilities: | Unearned revenue | 387.8 | 439.1 |
| Current liabilities: | Short-term operating lease liabilities | 180.3 | 191.1 |
| Current liabilities: | Short-term finance lease liabilities | 4.7 | 4.6 |
| Current liabilities: | Short-term borrowings and current portion of long-term debt | 0.9 | 500.1 |
| Current liabilities: | Total current liabilities | 2,124.6 | 2,823.5 |
| Current liabilities: | Long-term debt | 5,857.6 | 5,084.6 |
| Current liabilities: | Operating lease liabilities | 661 | 682.6 |
| Current liabilities: | Finance lease liabilities | 61.6 | 63 |
| Current liabilities: | Deferred income taxes and other tax liabilities | 486.7 | 454.5 |
| Current liabilities: | Other liabilities | 717.6 | 647.8 |
| Current liabilities: | Total liabilities | 9,909.1 | 9,756 |
| Commitments and contingent liabilities | Noncontrolling interest | 16.4 | 16.9 |
| Shareholders’ equity: | Common stock, 80.9 and 82.2 shares outstanding at June 30, 2026, and December 31, 2025, respectively | 7.3 | 7.5 |
| Shareholders’ equity: | Retained earnings | 8,701.4 | 8,639.9 |
| Shareholders’ equity: | Accumulated other comprehensive loss | -101.9 | -27.6 |
| Shareholders’ equity: | Total shareholders’ equity | 8,606.8 | 8,619.8 |
| Shareholders’ equity: | Total liabilities and shareholders’ equity | 18,532.3 | 18,392.7 |

### Cash Flow (Three Months Ended June 30, — (In Millions) (in millions))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES: | Net earnings | 299.1 | 238.3 | 577.1 | 451.3 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Depreciation and amortization | 179 | 170.3 | 352.3 | 337.1 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Stock compensation | 34.9 | 34.1 | 66.6 | 66.9 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Operating lease right-of-use asset expense | 49.1 | 50.8 | 97.1 | 99.4 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Deferred income taxes | 24.4 | -6.1 | 26.4 | -12.2 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | Other, net | 14.2 | 38 | 25.6 | 46.1 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | (Increase) decrease in accounts receivable | -59.2 | 30.9 | -247.1 | -139.9 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | (Increase) decrease in unbilled services | -0.7 | 0.9 | -6.9 | 4.8 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | Increase in supplies inventory | -65.1 | -11.9 | -29.7 | -3.5 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | Decrease in prepaid expenses and other | 23.1 | 12.8 | 27.1 | 57.8 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | (Decrease) increase in accounts payable | -11.7 | 67 | -150.4 | -80.6 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | (Decrease) increase in unearned revenue | -17.6 | 0.2 | -49.7 | -8.7 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | Decrease in accrued expenses and other | -24 | -4.7 | -51.4 | -179.4 |
| Change in assets and liabilities (net of effects of acquisitions and divestitures): | Net cash provided by operating activities | 445.5 | 620.6 | 637 | 639.1 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Capital expenditures | -131.6 | -77.9 | -252.6 | -203.9 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Proceeds from sale of assets | 1.9 | 1.9 | 9.7 | 2.4 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Proceeds from sale or distribution of equity affiliates or other investments |  | 6.9 |  | 6.9 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Purchase of equity affiliates or other investments | -10.8 | -15 | -17.5 | -172 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Acquisition of businesses, net of cash acquired | -225.7 | -10 | -427.9 | -63.5 |
